Nasus Pharma vs Supernus
Supernus reported revenue of $1.2 billion in fiscal 2025, about the same as Nasus Pharma's $1.2 billion in fiscal 2025. Nasus Pharma had an operating margin of -0.4%, against 21.1% at Supernus. Free cash flow was −$5 million at Nasus Pharma and −$93 million at Supernus.
Side by side
| Nasus Pharma | Supernus | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $1.2B | $1.2B |
| Revenue growth | — | 4.3% |
| Revenue growth a year, last 5 years | — | — |
| Gross margin | — | 80.2% |
| Operating margin | −0.4% | 21.1% |
| Net margin | −0.5% | 16.9% |
| Free cash flow | −$5M | −$93M |
| Free cash flow margin | −0.4% | −7.5% |
| Return on capital | — | — |
| Net debt to EBITDA | — | 0.5x |
| Dividends and buybacks | $0M | $11M |
| Change in diluted share count | 14.0% | −3.8% |
| Last close | $2.55 | $28.35 |
| P/E at the last close | — | 7.9× |
| Insider trades, last 12 months | bought $61,809, sold $0 | bought $229,274, sold $2.8 million |
| Piotroski F-score | — | 4 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Nasus PharmaSupernus
Operating margin
Percent of revenue
Nasus PharmaSupernus
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Nasus PharmaSupernus
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Nasus Pharma and Supernus pages.